Demographic data.

<p>IV = intravenous</p><p>SC = subcutaneous</p><p>FEV1 –forced expiratory volume in 1 second</p><p>FEV1%—percentage of average normal predicted FEV1 value</p><p>FVC–forced vital capacity</p><p>*one person switched from IV to SC</p><p>Demographic data.</p

Flowchart of study population identified for analysis.

<p>Flowchart of study population identified for analysis.</p

Rate of AECOPD events before and after Ig treatment classified by stage of COPD based on GOLD criteria, presence or absence of radiographic bronchiectasis, or baseline IgG level.

<p>IgG = 5.9 g/L is the median IgG in our case series.</p><p>Rate of AECOPD events before and after Ig treatment classified by stage of COPD based on GOLD criteria, presence or absence of radiographic bronchiectasis, or baseline IgG level.</p

Age and sex standardized incidence rates (per 1000 individuals) for COPD, asthma and concurrent physician-diagnosed asthma and COPD over time among adults 35 years and older in Ontario, Canada.

<p>Age and sex standardized incidence rates (per 1000 individuals) for COPD, asthma and concurrent physician-diagnosed asthma and COPD over time among adults 35 years and older in Ontario, Canada.</p

All exacerbations per year before and after Ig treatment in each studied patient.

<p>All exacerbations per year before and after Ig treatment in each studied patient.</p

Total number of exacerbations per year in each class of exacerbation the year before and the year after Ig treatment.

<p>Black bars represent numbers of exacerbations before Ig treatment. White bars represent numbers of exacerbations after Ig treatment. See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142205#sec006" target="_blank">Methods</a> section for definition of each class of COPD exacerbation. The overall decrease in number of exacerbations ignoring the clustering of events among patients was an 84.9% reduction in moderate AECOPD events, 91.7% in severe AECOPD events and 86.2% in moderate or severe AECOPD.</p

Age and sex standardized prevalence rates (%) for COPD, asthma and concurrent physician-diagnosed asthma and COPD over time among adults 35 years and older in Ontario, Canada.

<p>Age and sex standardized prevalence rates (%) for COPD, asthma and concurrent physician-diagnosed asthma and COPD over time among adults 35 years and older in Ontario, Canada.</p

Trends in concurrent physician-diagnosed asthma and COPD prevalence, incidence and mortality over time (increase with calendar year) adjusted for sex and age in generalized linear model.

<p>Trends in concurrent physician-diagnosed asthma and COPD prevalence, incidence and mortality over time (increase with calendar year) adjusted for sex and age in generalized linear model.</p

All-cause mortality standardized rates (%) by age and sex for COPD, asthma and concurrent physician-diagnosed asthma and COPD over time among adults 35 years and older in Ontario, Canada.

<p>All-cause mortality standardized rates (%) by age and sex for COPD, asthma and concurrent physician-diagnosed asthma and COPD over time among adults 35 years and older in Ontario, Canada.</p

The association between concurrent physician-diagnosed asthma and COPD compared to COPD or asthma with all-cause, cardiovascular and respiratory mortality rates adjusted for time (calendar year), sex, and age.

<p>The association between concurrent physician-diagnosed asthma and COPD compared to COPD or asthma with all-cause, cardiovascular and respiratory mortality rates adjusted for time (calendar year), sex, and age.</p